BR0210391A - Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto - Google Patents

Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto

Info

Publication number
BR0210391A
BR0210391A BR0210391-5A BR0210391A BR0210391A BR 0210391 A BR0210391 A BR 0210391A BR 0210391 A BR0210391 A BR 0210391A BR 0210391 A BR0210391 A BR 0210391A
Authority
BR
Brazil
Prior art keywords
compound
patient
disease
treating
methods
Prior art date
Application number
BR0210391-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Shon R Pulley
James P Beck
Ruth E Tenbrink
Jon S Jacobs
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of BR0210391A publication Critical patent/BR0210391A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
BR0210391-5A 2001-06-12 2002-06-12 Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto BR0210391A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29750501P 2001-06-12 2001-06-12
US33308201P 2001-11-19 2001-11-19
PCT/US2002/018719 WO2002100399A1 (en) 2001-06-12 2002-06-12 Macrocycles useful in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0210391A true BR0210391A (pt) 2004-06-15

Family

ID=26970188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210391-5A BR0210391A (pt) 2001-06-12 2002-06-12 Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto

Country Status (6)

Country Link
US (2) US7067507B2 (https=)
EP (1) EP1395257A1 (https=)
JP (1) JP2005505506A (https=)
BR (1) BR0210391A (https=)
CA (1) CA2450167A1 (https=)
WO (1) WO2002100399A1 (https=)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040167A1 (es) * 2002-03-28 2004-05-26 Novartis Ag Amidas del acido sulfamico
CA2485167A1 (en) * 2002-05-07 2003-11-20 The Government Of The United States Of America Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
KR20080058509A (ko) * 2002-06-11 2008-06-25 일라이 릴리 앤드 캄파니 흥분성 아미노산의 전구약물
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004062625A2 (en) 2003-01-07 2004-07-29 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315572A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315571A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) * 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
KR101113630B1 (ko) * 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
AU2004257025B9 (en) * 2003-06-27 2010-05-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
CA2554050A1 (en) * 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as cholinergic receptor modulators
DE602005015682D1 (de) * 2004-02-04 2009-09-10 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
US20070160537A1 (en) * 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
ATE490959T1 (de) * 2004-03-31 2010-12-15 Janssen Pharmaceutica Nv Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
US7423147B2 (en) * 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
WO2006010095A2 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
MX2007000480A (es) * 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
US7494986B2 (en) * 2004-07-20 2009-02-24 Bristol-Myers Squibb Company Cycloalkylamine derivatives as NK-1/SSRI antagonists
CA2575340A1 (en) * 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP2008511643A (ja) * 2004-08-27 2008-04-17 エラン ファーマシューティカルズ，インコーポレイテッド 置換エタノール環式アミンアスパラギン酸プロテアーゼ阻害剤を用いて、アミロイドーシスを治療する方法
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006047415A2 (en) * 2004-10-26 2006-05-04 Janssen Pharmaceutica, N.V. Factor xa compounds
US7678783B2 (en) * 2004-11-17 2010-03-16 Merck Sharp & Dohme Corp. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
UY29223A1 (es) * 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
US7951949B2 (en) 2004-11-23 2011-05-31 Merck, Sharp & Dohme, Corp. Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NZ590148A (en) * 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
KR20070102514A (ko) * 2005-01-13 2007-10-18 노파르티스 아게 Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물
GB0504960D0 (en) * 2005-03-10 2005-04-20 Arakis Ltd Benzoxazocines
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
US7851474B2 (en) * 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
EP1966198B1 (en) 2005-10-25 2011-03-16 Janssen Pharmaceutica NV 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace)
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
TW200732296A (en) * 2005-12-15 2007-09-01 Astrazeneca Ab Novel compounds
DE102005062986A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
AU2007216531A1 (en) * 2006-02-14 2007-08-23 Neurosearch A/S Novel diazabicycloalkane derivatives and their medical use
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
CA2645289A1 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
WO2007110363A1 (en) * 2006-03-24 2007-10-04 Neurosearch A/S Novel guanidine derivatives and their medical use
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US20090118265A1 (en) * 2006-05-23 2009-05-07 Dan Peters Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
AU2007267177A1 (en) * 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
UA100669C2 (ru) * 2006-06-01 2013-01-25 Санофі-Авентіс Спироциклические нитрилы как ингибиторы протеазы, способ их получения (варианты) и лекарственное средство на их основе
JP2009542778A (ja) * 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
BRPI0715437A2 (pt) * 2006-07-20 2013-04-16 Novartis Ag lactamas macrocÍclicas
JP2009544599A (ja) * 2006-07-20 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物
CA2679735A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
WO2008116302A1 (en) * 2007-03-26 2008-10-02 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
JP2010536725A (ja) * 2007-08-17 2010-12-02 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルオキサジアゾリル誘導体
US7935695B2 (en) * 2007-08-17 2011-05-03 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN101868454A (zh) * 2007-11-20 2010-10-20 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物
JP5498392B2 (ja) * 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
WO2009097278A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
EP2240472B1 (en) 2008-01-29 2012-11-21 Janssen Pharmaceutica NV 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
EP2427451B1 (en) * 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
BRPI1011683B8 (pt) * 2009-06-19 2021-05-25 D Western Therapeutics Inst Inc derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
AU2010262643B2 (en) * 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN103596955B (zh) * 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
DK2721012T3 (en) 2011-06-17 2016-08-15 Lilly Co Eli Biclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives as MGLU2 receptor agonist
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US20150141500A1 (en) * 2012-05-10 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological diseases
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
FR2993563B1 (fr) * 2012-07-20 2015-12-18 Metabrain Res Derives de thiophenes utiles dans le traitement du diabete
CA2887598A1 (en) 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
WO2014075676A1 (en) * 2012-11-15 2014-05-22 V-Biotek Holding Aps Amines from trigonella foemum - graecum
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR20160115936A (ko) * 2014-02-19 2016-10-06 하. 룬드벡 아크티에셀스카브 알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
MY180575A (en) 2014-04-11 2020-12-02 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
JP2015227329A (ja) * 2014-05-09 2015-12-17 サントリーホールディングス株式会社 メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤
WO2015195950A1 (en) * 2014-06-20 2015-12-23 Principia Biophamram Inc. Lmp7 inhibitors
ES2717510T3 (es) * 2014-09-17 2019-06-21 Oncodesign Sa Inhibidores macrocíclicos de cinasa LRRK2
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US10647679B2 (en) * 2015-03-15 2020-05-12 Emory University N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
EP3334720A1 (en) 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
MA45599A (fr) * 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
EP3493803A4 (en) * 2016-08-05 2020-04-22 The Regents of The University of California GP130 MODULATORS
SMT202200331T1 (it) * 2016-10-05 2022-09-14 Nsc Therapeutics Gmbh Polimorfi cristallini di un agonista di recettore muscarinico di acetilcolina
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US20190388425A1 (en) * 2017-01-20 2019-12-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018167176A1 (en) * 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
CA3058198A1 (en) * 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
EP3625232B1 (en) * 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
GB201712567D0 (en) * 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2021123883A1 (en) * 2019-12-19 2021-06-24 Latvian Institute Of Organic Synthesis Macrocyclic amides acting as plasmepsin inhbitors for the treatment of malaria
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors

Also Published As

Publication number Publication date
CA2450167A1 (en) 2002-12-19
US7067507B2 (en) 2006-06-27
US20060003978A1 (en) 2006-01-05
EP1395257A1 (en) 2004-03-10
JP2005505506A (ja) 2005-02-24
US7456163B2 (en) 2008-11-25
WO2002100399A1 (en) 2002-12-19
US20030236240A1 (en) 2003-12-25

Similar Documents

Publication Publication Date Title
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
BR0112000A (pt) Amina, composto, álcool, epóxido, cetona, azida, composição, uso de uma amina, métodos de tratamento de um paciente, de inibição da atividade da beta-secretase, de clivagem da proteìna precursora de amilóide e da produção de peptìdeo amilóide e de placa beta-amilóide em um animal, de tratamento ou prevenção de uma doença distinguida por depósitos de beta-amilóide no cérebro e de produção de um complexo de beta-secretase, e, kit
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
NO994016L (no) Heterocykliske forbindelser og deres anvendelse for inhibering av <beta>amyloidpeptid
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0213743A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0113590A (pt) 7-oxo-piridopirimidinas
WO2002100818A3 (en) Aminediols as agents for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO RPI 2108 DE 31/05/2011.